Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences develops CRISPR genome-edited, allogeneic CAR-T cell therapies for hematologic malignancies. Company updates center on vispacabtagene regedleucel, or vispa-cel, an anti-CD19 CAR-T therapy being evaluated in B cell non-Hodgkin lymphoma and large B cell lymphoma, and CB-011, an anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma.
Recurring announcements include clinical and translational data from the ANTLER and CaMMouflage trials, FDA designations and trial-design interactions, financial results, research and development spending, cash resources, pipeline prioritization, and medical or investor conference participation.
Caribou Biosciences, Inc. (Nasdaq: CRBU) reported its first quarter 2024 financial results and pipeline progress, highlighting advancements in clinical-stage programs for hematologic malignancies and autoimmune diseases. With $345.9 million in cash, cash equivalents, and marketable securities, the company expects to fund operations into Q1 2026. Notable milestones include presenting clinical data at the 2024 ASCO Annual Meeting, initiating the GALLOP Phase 1 trial, and providing updates on ongoing trials. Despite a slight decrease in licensing and collaboration revenue, increased R&D and G&A expenses led to a net loss of $41.2 million for Q1 2024.
Caribou Biosciences, Inc. (Nasdaq: CRBU) will participate in upcoming investor conferences, including the 2024 RBC Capital Markets Global Healthcare Conference and BofA Securities 2024 Health Care Conference. The company will present at these events, offering webcasts for more information.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.